Swedish Company Sobi, Savient To Promote Kineret in United States

Swedish Orphan Biovitrum AB (Sobi) and Savient Pharmaceuticals Inc. Feb. 19 announced that they have entered into an agreement to co-promote Kineret (anakinra) in the United States.

Kineret is indicated for the treatment of rheumatoid arthritis in patients 18 years of age or older. It also received approval from the Food and Drug Administration in January for the treatment of children and adults with the severe form of cryopyrin-associated periodic syndromes (CAPs) called neonatal-onset multisystem inflammatory disease.

Under the terms of the agreement, Sobi has granted Savient the exclusive right to co-promote Kineret in the United States. Savient will market ...